Abstract
This research study aims to discern the mechanism(s) responsible for the cardiac benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors induce systemic ketosis, but whether this is a mechanism of benefit in relation to improved cardiac function is currently unclear. To further elucidate this relationship, the effect of increased ketone concentration (with infusion of beta-hydroxybutyrate [BOHB]) on left ventricular (LV) function and myocardial glucose uptake (MGU) was done.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
